Ethinyloestradiol-Levonorgestrel versus Low-Dose Spironolactone-Pioglitazone-Metformin (SPIOMET) for Adolescent Girls with Polycystic Ovary Syndrome: On-Treatment and Post-Treatment Observations
Latest Information Update: 11 Oct 2023
Price :
$35 *
At a glance
- Drugs Ethinylestradiol/levonorgestrel (Primary) ; Metformin; Pioglitazone; Spironolactone
- Indications Hyperandrogenism; Hyperinsulinaemia; Polycystic ovary syndrome
- Focus Therapeutic Use
- 08 Oct 2023 Results of post hoc pooled analysis assessing the pooled pre-treatment data of 65 adolescent girls with PCOS-without-obesity in three reported studies (ISRCTN 45546616; 29234515; 11062950) and the results of 24 adolescent girls with PCOS-without-obesity, who received pioglitazone (7.5 mg/d for 1 year) as part of a randomized combination treatment (with spironolactone and metformin) in two reported studies (29234515; 11062950), published in the Journal of Endocrinological Investigation.
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 04 Feb 2013 New trial record